These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 8993528)
1. Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis. Rudnicka L; Czuwara J; Barusińska A; Nowicka U; Makieła B; Jabłonska S Ann N Y Acad Sci; 1996 Dec; 803():318-20. PubMed ID: 8993528 [No Abstract] [Full Text] [Related]
2. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]. Tsunoda T Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938 [No Abstract] [Full Text] [Related]
3. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. Czuwara-Ladykowska J; Makiela B; Smith EA; Trojanowska M; Rudnicka L Arthritis Res; 2001; 3(5):311-8. PubMed ID: 11549373 [TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase I inhibitors. Takimoto CH; Kieffer LV; Arbuck SG Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210 [No Abstract] [Full Text] [Related]
6. DNA topoisomerase I poisons. Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479 [No Abstract] [Full Text] [Related]
7. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Jacob S; Aguado M; Fallik D; Praz F Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654 [TBL] [Abstract][Full Text] [Related]
8. Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid. Zhang GY; Gao WY; Li X; Yi CG; Zheng Y; Li Y; Xiao B; Ma XJ; Yan L; Lu KH; Han Y; Guo SZ Ann Plast Surg; 2009 Jul; 63(1):94-9. PubMed ID: 19546682 [TBL] [Abstract][Full Text] [Related]
9. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance. Desai SD; Mao Y; Sun M; Li TK; Wu J; Liu LF Ann N Y Acad Sci; 2000; 922():306-8. PubMed ID: 11193908 [No Abstract] [Full Text] [Related]
10. DNA topoisomerase inhibitors. Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607 [No Abstract] [Full Text] [Related]
11. Topoisomerase-I inhibitors in the management of colon cancer. Willson JK Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519 [No Abstract] [Full Text] [Related]
12. Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma). Shoenfeld Y; Grunebaum E; Laufer M; Zurgil N; Bakimer R; Lunderschmidt A; Valentini G; Tirri G; Blank M Isr J Med Sci; 1996 Jul; 32(7):537-42. PubMed ID: 8756980 [TBL] [Abstract][Full Text] [Related]
13. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Champoux JJ Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925 [TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571 [TBL] [Abstract][Full Text] [Related]
19. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. Ajani JA Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):17-8. PubMed ID: 11200142 [No Abstract] [Full Text] [Related]
20. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks. Murren JR; Beidler DR; Cheng YC Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502 [No Abstract] [Full Text] [Related] [Next] [New Search]